Losartan Geriatric (65+) Dosing: Evidence-Based Guide

Published May 25, 2026Updated Sep 30, 2026Last reviewed May 25, 2026

11 linked public sourcesEditorial, sourcing, and corrections policy

Age 65 alone does not require a lower losartan starting dose. For hypertension, the labeled usual adult start is 50 mg once daily. A 25 mg start is recommended with possible volume depletion or mild-to-moderate liver impairment; the hypertension maximum is 100 mg daily. The right choice depends on the person's condition and current treatment. [1]

What changes the starting-dose decision?

Situation	What the prescribing information says
Adult hypertension	Usually start at 50 mg once daily.
Possible volume depletion, including some patients taking diuretics	Start at 25 mg once daily.
Mild-to-moderate hepatic impairment	Start at 25 mg once daily.
Kidney impairment without volume depletion	No routine initial dose adjustment solely for kidney impairment.
Older age	No separate age-based dose schedule.

These instructions concern losartan alone, not the fixed losartan/hydrochlorothiazide combination. [1]

The label reports similar losartan and active-metabolite concentrations in younger hypertensive adults and those aged 65 to 75. Frailty, poor intake, dizziness and other medicines still matter, but they should be assessed directly rather than assuming everyone over 65 processes the medicine the same way. [1]

What should be checked before and after a change?

A useful baseline includes blood pressure, kidney function, potassium and sodium. Review the full medicine list and recent problems such as poor intake, vomiting, dizziness or falls. [2]

The monitoring interval depends on the indication and risk:

For hypertension, NHS Specialist Pharmacy Service guidance checks kidney function and electrolytes within one to two weeks of starting or changing treatment, or within seven days when relevant risk factors are present.
KDIGO guidance for chronic kidney disease calls for blood pressure, creatinine and potassium assessment within two to four weeks, adjusted to kidney function and potassium status. [2,3]

Arrange the test date when the dose is changed. The practical question is not just whether a test was ordered, but who will review it and explain whether to continue the same dose.

A home blood-pressure record can include the date, reading, medication time and any symptoms. If standing causes dizziness, tell the clinician so posture-related measurements can be included. Avoid adjusting the dose from one isolated home reading.

Does an eGFR below 30 mean losartan must stop?

No. KDIGO specifically supports continuing an ACE inhibitor or ARB in people with CKD even when eGFR falls below 30 mL/min/1.73 m². The decision also depends on symptoms, potassium and the reason for treatment. [3]

KDIGO's early monitoring threshold concerns a serum creatinine rise greater than 30% within four weeks after initiation or a dose increase. It is not interchangeable with a 30% fall in eGFR. Symptomatic low blood pressure or high potassium that remains uncontrolled despite treatment can justify reducing or stopping the medicine. [3]

A new abnormal result therefore needs interpretation alongside hydration, recent illness and interacting medicines. Do not treat a single eGFR value as an automatic stop instruction.

What benefits did the major trials find?

LIFE enrolled 9,193 adults aged 55 to 80 with hypertension and ECG evidence of left ventricular hypertrophy. Losartan-based treatment was compared with atenolol-based treatment. The primary cardiovascular outcome occurred in 508 versus 588 participants, a relative risk of 0.87. Fatal or nonfatal stroke occurred in 232 versus 309, a relative risk of 0.75. [4]

These were treatment-regimen comparisons in a defined population, not a trial proving that every older adult should start at 25 mg. They also do not establish the best starting regimen for every frail person over 80.

RENAAL studied 1,513 people with type 2 diabetes and nephropathy. Losartan 50 to 100 mg daily was added to conventional treatment and compared with placebo. Over a mean 3.4 years, it reduced the relative risk of the composite kidney/death outcome by 16% and end-stage kidney disease by 28%, without reducing overall mortality. [5]

This explains why someone may continue losartan for kidney protection even when the blood-pressure number is already satisfactory. Review the original indication before considering dose reduction.

Which blood-pressure target applies?

The 2025 AHA/ACC guideline gives an overall treatment goal below 130/80 mm Hg, with additional considerations for people requiring institutional care or with limited predicted lifespan. [6]

For an older adult, the appointment should connect that goal with actual function and symptoms: standing comfort, falls, everyday activity, other diseases and treatment burden. “Over 65” is too broad to describe all of those factors.

Repeated dizziness or a fall should trigger reassessment of the full regimen and measurements. Merely moving a dose to bedtime can miss the underlying cause.

Morning or bedtime?

The BedMed-Frail randomized trial studied 776 residents of Canadian continuing-care facilities, with a median age of 88. Moving once-daily blood-pressure medicines to bedtime did not significantly reduce the primary outcome of death or major cardiovascular events compared with usual care, which was mostly morning dosing. Falls and fractures also did not differ significantly. [7]

This trial included multiple antihypertensive medicines, not only losartan. Choose a consistent time that fits the agreed regimen and daily routine. If symptoms repeatedly occur after a dose, document the pattern so the clinician can review the medicine, dose and timing together.

Which other medicines should be reviewed?

Include over-the-counter products in the list. The NHS identifies NSAIDs such as ibuprofen, medicines or supplements that raise potassium, lithium and other blood-pressure medicines as combinations needing review with losartan. [8]

For someone also taking a diuretic, a new NSAID course and reduced fluid intake can be particularly relevant to a kidney-function change. A pharmacist can check the actual product and intended duration. Do not assume an over-the-counter medicine is irrelevant to the prescription plan.

Combining an ARB with an ACE inhibitor or direct renin inhibitor is discouraged in CKD. Adding medicines that affect the same system is not automatically a better way to protect the kidneys. [3]

When can reducing treatment make sense?

Persistent symptomatic low blood pressure, recurrent falls, changed health priorities or a difficult medication burden can prompt a supervised review. The review should consider all indications, including kidney disease, rather than choosing losartan for withdrawal simply because it is familiar.

In OPTiMISE, 569 selected adults aged 80 or older, with systolic pressure below 150 mm Hg and at least two antihypertensive medicines, were randomized to removal of one medicine or usual care. At 12 weeks, 86.4% versus 87.7% maintained systolic pressure below 150 mm Hg; the reduction strategy met the trial's noninferiority criterion. [9]

Longer follow-up found no evidence of increased hospitalization or mortality over a median four years. About half of surviving participants in the reduction group maintained the reduction. These results support a monitored option for selected patients, not automatic withdrawal for everyone reaching age 80. [10]

Does gout affect the choice?

The American College of Rheumatology conditionally recommends choosing losartan preferentially as an antihypertensive when feasible in patients with gout. That consideration belongs alongside blood-pressure control and other indications; it does not mean losartan replaces the person's gout treatment. [11]

Comparing ARBs also involves duration of effect, tolerability, the conditions being treated and the practical cost of filling the prescription. Bring the pharmacy's actual price and coverage information if cost is interrupting treatment.

What should prompt earlier contact?

Report new standing dizziness, fainting, a fall, marked weakness, palpitations or an unexpected laboratory result promptly. Fainting, chest pain, confusion, severe weakness with an irregular heartbeat or an injury from a fall needs urgent assessment. Keep the dose and medication list available when seeking care.

At routine follow-up, confirm three things: the reason for losartan, the agreed blood-pressure target and the next kidney-function/potassium check. Those details make a dosing plan usable between appointments.

References

Evidence overview for losartan: Losartan Geriatric (65+) Dosing: Evidence-Based Guide